AOD-9604

Definition

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH176-191) that was designed to isolate the fat-burning region of GH while eliminating its growth-promoting and insulin-antagonizing properties. It has undergone human clinical trials — Phase 1, 2, and limited Phase 3 trials — for obesity treatment, which gives it more human trial data than many peptides in the longevity space. Phase 3 trials did not demonstrate sufficient weight loss efficacy for FDA drug approval as an obesity medication. Mechanism of action involves stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat synthesis) through pathways distinct from full GH. Its clinical use in functional and longevity medicine contexts remains off-label. FDA regulatory status for compounding is subject to ongoing review.

Frequently Asked Question

Did AOD-9604 pass clinical trials for weight loss?

AOD-9604 was developed specifically as an obesity drug and completed human trials including limited Phase 3 testing. The Phase 3 trials did not demonstrate sufficient weight loss efficacy for FDA drug approval as an obesity medication — meaning it did not outperform the placebo by the margin required for approval. This is why it does not have FDA approval for weight loss. Its preclinical fat-burning mechanism is well-characterized, but clinical translation to meaningful weight loss in humans has been modest at standard doses.

How is AOD-9604 different from GLP-1 medications for weight loss?

GLP-1 medications (semaglutide, tirzepatide) have robust Phase 3 clinical trial data showing 15 to 22% average weight loss and are FDA-approved for chronic weight management. AOD-9604's clinical trial data showed modest effects insufficient for drug approval. The two work through entirely different mechanisms — GLP-1 agents affect appetite and satiety centrally; AOD-9604 targets fat tissue metabolism directly. They are not interchangeable or comparably effective for most patients.

Is AOD-9604 approved for any use in the United States?

FDA GRAS — Generally Recognized as Safe — is a designation that applies to food additives, not drugs. It confirms that a substance is considered safe for its designated food use based on expert review. For AOD-9604, GRAS status covers its use as a food ingredient — it says nothing about safety or efficacy for clinical therapeutic use as an injectable peptide at pharmacological doses. Patients should not interpret FDA GRAS status as equivalent to FDA drug approval or as confirmation that a substance is safe for injection at clinical doses. SPOKEmed distinguishes these regulatory categories explicitly when discussing AOD-9604 with patients.

Why AOD-9604 Matters

AOD-9604 is notable in the peptide space for a specific reason: it was actually developed as a pharmaceutical drug and completed human clinical trials through Phase 3. This gives it more human safety and pharmacokinetic data than the majority of research-stage peptides being discussed in longevity medicine. However, 'more data than most' does not mean 'proven effective' — the Phase 3 trial for obesity treatment did not demonstrate the degree of weight loss required for FDA drug approval. This clinical history makes AOD-9604 a more transparently understood peptide than most, but also one where the evidence base is clear: mechanistically interesting preclinical data, human safety profile established, clinical efficacy for weight loss modest at studied doses.

How Spokmed Company Uses It

AOD-9604 is not a primary or established component of SPOKEmed's weight management protocols. Its FDA GRAS (Generally Recognized as Safe) status as a food additive and history of human clinical trials make it a peptide SPOKEmed can evaluate for appropriate patients — but its use requires confirmation that current compounding availability meets applicable regulations, individual clinical assessment confirming a specific rationale beyond the GLP-1 medications that have far stronger clinical evidence, and full transparency to the patient about its evidentiary status.

Related Services

Related Terms

"AOD-9604" Appears in These Categories

Targeted Peptide Support